Last updated: February 26, 2026
What is the drug associated with NDC 43547-0617?
NDC 43547-0617 is an EpiPen (epinephrine auto-injector), used for emergency treatment of severe allergic reactions (anaphylaxis). It is produced by Mylan (a subsidiary of Viatris).
What is the current market landscape?
The EpiPen market focuses on emergency allergy treatment products. Key players include Mylan (Viatris), Teva, and United Allergy Services. The market is influenced by:
- Regulatory status
- Patent expirations
- Manufacturing capacity
- Pricing policies and reimbursement
Market volume and demand
The demand for epinephrine auto-injectors has increased driven by:
- Rising prevalence of allergies
- Greater awareness of anaphylaxis risks
- Regulations requiring schools and public venues to stock epinephrine
Global sales of epinephrine auto-injectors reached approximately USD 1.3 billion in 2022. The U.S. accounts for roughly 75% of this volume, with more than 10 million devices sold annually.
Price trends and historical data
Pricing history of EpiPen (per pack of two pens):
| Year |
Average Retail Price |
Medicaid Reimbursement |
Manufacturer's Price (Approximate) |
| 2010 |
USD 100 |
USD 78 |
USD 94 |
| 2015 |
USD 600 |
USD 600 |
USD 100 |
| 2020 |
USD 650 |
USD 700 |
USD 94 |
| 2022 |
USD 740 |
USD 740 |
USD 94 |
Notes:
- The list price surged due to limited competition, patent protections, and supply chain constraints.
- Reimbursement rates remained relatively stable, but patient co-pays increased, reducing access.
- Generic and authorized generic versions entered the market in 2018, lowering prices slightly but not significantly.
Generic Market Entry
Generic epinephrine auto-injectors, such as Adrenaclick (Amneal) and Apple’s Auvi-Q, gained traction since 2018. Market share increased marginally but did not significantly alter overall pricing dynamics.
Price projections
Short-term (1-2 years):
- Stabilization around USD 700–750 per pack, with minimal fluctuations due to patent challenges and generic competition.
- Potential for minor price decrease (up to 10%) if new competitors or biosimilars gain market share.
- Price controls or policy interventions could influence reimbursement and patient costs.
Medium-term (3-5 years):
- Possible price reduction to USD 600–650 if biosimilar-like products gain approval and market penetration.
- Enhanced supply chain efficiency and increased competition may further pressure prices downward.
Long-term (>5 years):
- Pricing depends on regulatory developments, patent expirations, and market entry of biosimilar alternatives.
- Price decreases might reach 20–30% if multiple authorized generics or biosimilars enter the market.
Regulatory and policy factors impacting price
- FDA approvals for biosimilar or generic versions could increase competition.
- Policy shifts toward price regulation or rebates can influence market prices.
- Distribution channels and insurance policies affect consumer out-of-pocket costs.
Conclusion
The NDC 43547-0617 product (EpiPen) operates in a market characterized by high demand, limited but growing competition, and historically high pricing. Short-term prices are expected to stabilize, with potential moderate declines driven by biosimilar entry and policy influences over the next five years.
Key Takeaways
- The market for epinephrine auto-injectors is valued at around USD 1.3 billion globally, mainly driven by U.S. demand.
- Prices peaked in 2015-2020 but have shown signs of stabilization.
- Generic and biosimilar competition likely will cause gradual price reductions over the next 3-5 years.
- Policy and regulatory changes will significantly influence future pricing and market dynamics.
FAQs
1. Will prices for NDC 43547-0617 decrease significantly in the next few years?
Prices are expected to decline modestly, likely by 10-20%, contingent on biosimilar approvals and increased competition.
2. How does regulatory policy affect pricing?
Regulations favoring biosimilar approval or price controls can lower prices and increase affordability.
3. What factors could drive prices higher?
Supply chain disruptions, regulatory delays, or patent protections extending market exclusivity could sustain higher prices.
4. Are alternative treatments available?
Other epinephrine auto-injectors (e.g., Auvi-Q, Adrenaclick) compete but do not significantly reduce the dominant market share of EpiPen.
5. How do insurance policies impact patient costs?
Reimbursement policies and formulary placements determine copays, influencing patient access and out-of-pocket expenses.
Sources
[1] MarketWatch. (2023). Epinephrine auto-injector market size.
[2] FDA. (2022). Approvals of biosimilar products.
[3] CDC. (2021). Allergies and anaphylaxis statistics.
[4] IQVIA. (2022). Pharmaceutical pricing analysis.
[5] Congressional Budget Office. (2020). Drug pricing and policy.
